Biomarkers /
MLLT3
Overview
Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 3 (MLLT3) is a gene that encodes for a protein involved in cell growth and maintenance (GenAtlas 2013). In cancer, rearrangements involving MLLT3 have been observed in AML. MLLT3 is also known as AF9.
MLLT3 is altered in 0.20% of all cancers with acute myeloid leukemia, endometrial endometrioid adenocarcinoma, colon adenocarcinoma, breast invasive ductal carcinoma, and lung adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in MLLT3 are MLLT3-KMT2A Fusion (0.10%), MLLT3 Fusion (0.05%), MLLT3 S190dup (0.82%), MLLT3 S190del (1.04%), and MLLT3 D323N (1.85%) [3].
Clinical Trials
Significance of MLLT3 in Diseases
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma And Classical Hodgkin Lymphoma +
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.